Innovative Cancer Treatments Spotlighted at NeauxCancer Conference
The Innovation Track at the conference highlights groundbreaking biotech and healthcare advancements in oncology.
ImmunoGenesis, a dynamic clinical-stage biotech firm focused on cutting-edge immunotherapies, is gearing up for an exciting participation in the much-anticipated 2025 NeauxCancer Conference, organized by the Cancer Advocacy Group of Louisiana (CAGLA). This event promises to bring together a diverse array of professionals from the healthcare sector, aimed at sharing and discussing revolutionary approaches to cancer treatment.
At the conference, scheduled from March 27 to 29, ImmunoGenesis will be represented by its President and CEO, James Barlow. He is set to share insights on the company’s ambitions to redefine the field of immuno-oncology through a unique pipeline of products designed specifically to address immune resistance issues prevalent in cancer treatments. Barlow will provide an update on the promising Phase 1a/1b clinical study of their lead compound, IMGS-001. This innovative dual-specific PD-L1/PD-L2 antibody is engineered to effectively target immune-excluded tumors, which are notoriously resistant to current methods of immunotherapy.
Beyond the insights on IMGS-001, Barlow will delve into the recently initiated Phase 2 trial for another significant asset, IMGS-101 (evofosfamide). This hypoxia reversal agent is being evaluated in conjunction with checkpoint inhibition therapies, potentially marking a significant step forward in the treatment landscape.
The conference aims to attract oncologists and healthcare professionals eager to engage in meaningful discussions about the latest practices and advancements in cancer care. The Innovation Track is especially designed to foster learning on emerging technologies that could redefine treatment protocols and enhance patient outcomes.
Chadwick K. Landry, Portfolio Manager at Poydras Capital Partners and CAGLA President, expressed enthusiasm about ImmunoGenesis participating in this year’s Innovation Track. He stated, "ImmunoGenesis has recently expanded its clinical trials for IMGS-001 to a prominent cancer center, a remarkable opportunity for both clinicians and investors to gain firsthand insights into their innovative approaches. This conference serves as a platform for essential dialogue among industry stakeholders. "
For those interested in investing, registration for the conference is complimentary, providing a unique opportunity for investors to connect with pioneering companies in the oncology sector, such as ImmunoGenesis.
Key Details About the Innovation Track
ImmunoGenesis Presentation
ImmunoGenesis will present on Friday, March 28 at 2:00 PM CST. Attending this session will provide attendees with firsthand insights into their clinical advancements and strategies.
Conference Registration Information
Investors wishing to attend can register at no charge, ensuring that more voices can be brought into the conversation about the future of cancer treatment.
Significant Compliance and Accreditation
The 2025 NeauxCancer Conference is carefully structured to adhere to the accreditation standards of the Accreditation Council for Continuing Medical Education (ACCME). This commendable effort is realized through joint collaboration with the Ochsner Clinic Foundation, which is fully accredited by the ACCME to provide vital continuing medical education for healthcare providers.
About ImmunoGenesis
ImmunoGenesis aims to critically change the paradigm of immuno-oncology through innovative treatments targeting the intricate mechanisms behind immune resistance. Their flagship product, IMGS-001, is in advanced clinical trials targeting cold tumors that constitute a significant challenge within cancer care. Following the principle of addressing unique tumor characteristics, ImmunoGenesis focuses on overcoming the obstacles posed by immune exclusion, thereby stimulating a more robust immune response.
For further inquiries about the company’s pipeline and developments, please do not hesitate to reach out directly to ImmunoGenesis.
Frequently Asked Questions
What is the main focus of ImmunoGenesis?
ImmunoGenesis specializes in developing innovative immunotherapies aimed at transforming the treatment of cancers, particularly those resistant to existing therapies.
Who is presenting at the NeauxCancer Conference?
James Barlow, the President and CEO of ImmunoGenesis, will present at the conference, sharing insights about their clinical trial progress.
When is the presentation scheduled?
ImmunoGenesis's presentation is set for March 28 at 2:00 PM CST during the conference.
How does the conference benefit attendees?
The conference allows healthcare professionals and investors to learn about the latest advancements in cancer treatment and network with leading biotechnology companies.
Is there a cost for investors to attend the conference?
Registration for investors to attend the conference is complimentary, ensuring accessibility to groundbreaking discussions and presentations.
